Incidence of idiopathic intracranial hypertension in individuals with gonadotropin-releasing hormone analogue treatment for gender dysphoria in sweden

HIGHLIGHTS

• who: American Medical Association from the goserelin, GnRHa medications not included in the FDA warning, are also prescribed in SwedenAlthough unlikely, different pharmaceutical formulations could have different risk profiles. According to the FDA report, all , individuals developed IIH within , days of starting GnRHa and all but , had precocious puberty as the underlying condition (the sixth patient had GD). In our study, % of individuals with GD and GnRHa treatment were followed up for at least , days, thus allowing enough time to capture the outcome of IIH. In our data, no people with precocious puberty developed IIH. Study limitations . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.